The subsidiary of Zhejiang Jiuzhou Pharmaceutical (603456.SH) has obtained the registration certificate for hydrobromic acid fluoxetine tablets.

Zhejiang Jiuzhou Pharmaceutical (603456.SH) announced that its wholly-owned subsidiary Jiuzhou Biopharmaceutical (Taizhou) Co., Ltd. (formerly Zhejiang Siwei Pharmaceutical Technology Co., Ltd.) has recently received the "Drug Registration Certificate" for the Hydrobromide Fluoxetine Tablets issued by the National Medical Products Administration. Hydrobromide Fluoxetine Tablets are mainly used for the treatment of major depressive disorder (MDD) in adults. The tablets were jointly developed by H. Lundbeck A/S from Denmark and Takeda from Japan. They were approved for sale in the United States in September 2013 and in China in November 2017. Currently, the domestic manufacturers with the registration certificate for this drug include Chengdu Kanghong Pharmaceutical Group Co., Ltd. and Hunan Xiangzhong Pharmaceutical Co., Ltd. According to public data, the total sales revenue (at retail price) of Hydrobromide Fluoxetine Tablets in the domestic medical and retail market is estimated to reach 214 million RMB by 2024. As of now, the company has invested approximately 12.62 million RMB in research and development for the tablets.